CIK 0001453687 · Non-accelerated filer<br>Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-02 | DeSilva Nishan M Director | Grant or award | +178,000 | 185,000 | ||
| 2024-01-02 | DeSilva Nishan M Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | COX CARRIE SMITH Director | Grant or award | +178,000 | 390,881 | ||
| 2024-01-02 | COX CARRIE SMITH Director | Grant or award · Stock Option (Right to Buy) | +248,000 | 248,000 | ||
| 2024-01-02 | ZENNER PATRICK J Director | Grant or award | +178,000 | 233,248 | ||
| 2024-01-02 | ZENNER PATRICK J Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | Kalayoglu Murat Director | Grant or award | +178,000 | 435,739 | ||
| 2024-01-02 | Kalayoglu Murat Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | Kurtoglu Metin Chief Operating Officer | Grant or award | +1,531,000 | 1,531,000 | ||
| 2024-01-02 | Kurtoglu Metin Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +1,965,000 | 1,965,000 | ||
| 2023-12-22 | Singer Michael Director | Gift · Series A Convertible Preferred Stock | −3,000 | 3,304.56 | ||
| 2023-11-15 | SPRINGER TIMOTHY A Director | Grant or award | +24,785.08 | $403.47 | $10.0M | 24,785.08 |
| 2023-11-15 | SPRINGER TIMOTHY A Director | Grant or award | +123,925.41 | $403.47 | $50.0M | 123,925.41 |
| 2023-11-13 | Davis Blaine Chief Financial Officer | Returned to the company · Employee Stock Option (right to buy) | −1,250,000 | $0.79 | $988K | 0 |
| 2023-11-13 | Brunn Carsten President and CEO | Returned to the company | −55,000 | $2.06 | $113K | 728,081 |
| 2023-11-13 | Brunn Carsten President and CEO | Returned to the company | −13,600 | $2.06 | $28K | 714,481 |
| 2023-11-13 | Brunn Carsten President and CEO | Returned to the company | −169,725 | $2.06 | $350K | 544,756 |
| 2023-11-13 | Brunn Carsten President and CEO | Returned to the company | −282,800 | $2.06 | $583K | 261,956 |
| 2023-11-13 | Brunn Carsten President and CEO | Returned to the company · Employee Stock Option (right to buy) | −1,000,000 | 0 | ||
| 2023-11-13 | Brunn Carsten President and CEO | Returned to the company · Employee Stock Option (right to buy) | −330,000 | 0 |
Page 14 of 16 · 316 trades